Biol Reprod Lalor Postdoctoral Fellowships -- Application Deadline January 15, 2009
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

BOR - Papers in Press, published online ahead of print September 26, 2007.
Biol Reprod 2007, 10.1095/biolreprod.107.063479
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
78/1/35    most recent
biolreprod.107.063479v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zhang, H.
Right arrow Articles by Zhang, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zhang, H.
Right arrow Articles by Zhang, L.
Agricola
Right arrow Articles by Zhang, H.
Right arrow Articles by Zhang, L.
BIOLOGY OF REPRODUCTION 78, 35–42 (2008)
DOI: 10.1095/biolreprod.107.063479
© 2008 by the Society for the Study of Reproduction, Inc.

Role of Protein Kinase C Isozymes in the Regulation of alpha1-Adrenergic Receptor-Mediated Contractions in Ovine Uterine Arteries1

Hongying Zhang , and Lubo Zhang 2 

Center for Perinatal Biology, Department of Physiology & Pharmacology, Loma Linda University School of Medicine, Loma Linda, California 92350

ABSTRACT

Previously, we demonstrated that activation of protein kinase C (PRKC) enhanced alpha1-adrenergic receptor-induced contractions in nonpregnant ovine uterine arteries but inhibited the contractions in pregnant ovine uterine arteries. The present study tested the hypothesis that differential regulation of PRKC isozyme activities contributes to the different effects of phorbol 12, 13-dibutyrate (PDBu) on alpha1-adrenergic receptor-mediated contractions between the pregnant and nonpregnant ovine uterine arteries. Phenylephrine-induced contractions of ovine nonpregnant and pregnant uterine arteries were determined in the absence or presence of the PRKC activator PDBu and/or in combination with conventional and novel PRKC isozyme inhibitor GF109203X, PRKC isozyme-selective inhibitory peptides for conventional PRKC, PRKCB1, PRKCB2, and PRKCE. GF109203X produced a concentration-dependent inhibition of phenylephrine-induced contractions in both nonpregnant and pregnant uterine arteries, and it reversed the PDBu-mediated potentiation and inhibition of phenylephrine-induced contractions in nonpregnant and pregnant uterine artieries, respectively. In addition, PRKCB1, PRKCB2, and PRKCE inhibitory peptides blocked the PDBu-mediated responses in both nonpregnant and pregnant uterine arteries. Western blot analysis showed that PDBu induced a membrane translocation of PRKCA, PRKCB1, PRKCB2, and PRKCE in pregnant uterine arteries, and PRKCB1, PRKCB2, and PRKCE in nonpregnant uterine arteries. The results disprove the hypothesis that the dichotomy of PRKC mechanisms in the regulation of alpha1-adrenergic receptor-induced contractions in nonpregnant and pregnant uterine arteries is caused by the activation of different PRKC isozymes, and suggest downstream mechanisms of differential subcellular distributions for the distinct functional effects of PRKC isozymes in the adaptation of uterine arteries to pregnancy.

GF109203X, phenylephrine, phorbol 12, 13-dibutyrate, pregnancy, protein kinase C, protein kinase C inhibitor peptides

INTRODUCTION

During pregnancy, the uterine artery maintains low resistance, resulting from growth and vascular remodeling and relaxation to accommodate a large increase in uteroplacental blood flow to ensure normal fetal development. Multiple mechanisms are involved in the adaptation of uterine artery contractility during pregnancy [1–5]. Activation of {alpha}1 adrenergic receptors is an important mechanism in the regulation of uterine artery smooth muscle contractions [1, 6–9]. Protein kinase C (PRKC) plays a key role in {alpha}1-adrenergic receptor-mediated contractions of vascular smooth muscle [1, 10, 11] and pressure-dependent myogenic tone of the uterine artery [3, 5, 12]. Recently, we have demonstrated that activation of PRKC by phorbol-12, 13-dibutyrate (PDBu) potentiates {alpha}1-adrenergic receptor-induced contractions in uterine arteries from nonpregnant sheep (nonpregnant artery), but inhibits the contractions in uterine arteries from pregnant animals (pregnant artery) [13]. In addition, we have shown that differential regulations of the thick and thin filament pathways play an important role in the dichotomy of PRKC mechanisms in the regulation of {alpha}1-adrenergic receptor-induced contractions in nonpregnant and pregnant uterine arteries [14]. However, it remains unknown whether and to what extent to which activation of differential PRKC isozymes contributes to these pregnancy-specific effects of PDBu observed in the uterine arteries.

PRKC, a serine/threonine kinase family, consists of at least 11 isozymes that are further classified into three subfamilies: the conventional isozymes (PRKCA, PRKCB1, PRKCB2, and PRKCC), the novel isozymes (PRKCD, PRKCE, PRKCH, and PRKCQ), and the atypical isozymes (PRKCZ, PRKCI, and PRKC lambda). We have recently demonstrated that PRKCA, PRKCB, PRKCD, PRKCE, and PRKCZ isozymes are expressed in ovine uterine arteries [13]. If arteries from pregnant sheep are compared with those from nonpregnant animals, the basal activity of PRKCE is decreased, as is the expression level of PRKCA. In contrast, expression levels of PRKCB and PRKCZ are increased in arteries from pregnant sheep. Each PRKC isozyme has unique enzymatic properties, substrates, functions, and subcellular distributions in different blood vessels and species [11, 15–19]. Despite extensive studies, the physiologic role of each individual PRKC isozyme in the regulation of vascular contractility, including the uterine artery, remains unclear. This is likely due to the lack of highly selective pharmacologic agents to either inhibit or activate the isozymes. The aminoalkyl bisindolylmaleimide, GF109203X, has been demonstrated to be a potent and selective inhibitor of PRKC and to inhibit activity of conventional and novel PRKC isozymes [20–26]. More recent discovery of PRKC isozyme-selective translocation inhibitory peptides [27] allows determination of individual PRKC isozyme functions. Following activation, each PRKC isozyme translocates to its unique subcellular sites and binds to isozyme-specific anchoring proteins, receptors for activated C-kinase (RACKs). Each isozyme has a specific RACK-selective binding site that is exposed only after the activation of PRKC. PRKC isozyme-selective inhibitory peptides, containing isozyme-specific RACK-binding sites, have been demonstrated to inhibit translocation of the corresponding PRKC isozymes and, consequently, inhibit their isozyme-unique function [27–29].

The function of PRKC isozymes in the adaptation of uterine artery contractility during pregnancy is unknown. The present study tests the hypothesis that differential regulation of PRKC isozyme activities contributes to the different effects of PDBu on {alpha}1 adrenergic receptor-mediated contractions between the pregnant and nonpregnant uterine arteries. Concentration-response curves of phenylephrine-induced contractions of the uterine arteries were conducted in the absence or presence of PRKC activator PDBu and/or PRKC inhibitor GF109203X and PRKC isozyme-selective translocation inhibitory peptides. In addition, PDBu-mediated PRKC isozyme translocations were determined in the uterine arteries.

MATERIALS AND METHODS

Tissue Preparation

Tissues were prepared as previously described [13]. A total of 4–10 animals were used in each group. Nonpregnant and near-term pregnant (139.8 ± 0.2 days' gestation; range, 138–141 days) ewes were anesthetized with thiamylal (10 mg/kg) administered via the external left jugular vein. The ewes then were intubated, and anesthesia was maintained with 1.5%–2.0% halothane in O2 throughout the surgery. An incision was made in the abdomen to expose the uterus. The uterine arteries were isolated and removed without stretching and were placed in a modified Krebs solution (pH 7.4) of the following composition (in mM): 115.2 NaCl, 4.7 KCl, 1.80 CaCl2, 1.16 MgSO4, 1.18 KH2PO4, 22.14 NaHCO3, 0.03 EDTA, and 7.88 dextrose at room temperature. The Krebs solution was oxygenated with a mixture of 95%O2/5% CO2. After the tissues were removed, animals were killed with T-61 euthanasia solution (Hoechst-Roussel, Somerville, NJ). All procedures and protocols used in the present study were approved by the Animal Research Committee of Loma Linda University and followed the guidelines in the National Institutes of Health's "Guide for the Care and Use of Laboratory Animals."

Contraction Studies

The third (nonpregnant) and fourth (pregnant) branches of the main uterine arteries with similar external diameters were used in the present studies, as previously described [13]. Uterine arteries were dissected and cut into 2-mm ring segments, as previously described [3, 5, 13, 14, 30]. Isometric tension was measured in the Krebs solution in a tissue bath at 37°C as previously described [13]. Briefly, each ring was equilibrated for 60 min and then gradually stretched to the optimal resting tension as determined by the tension developed in response to 120 mM KCl added at each stretch level. Previous studies demonstrated that 120 mM KCl produced maximal contractions in the uterine arteries [3, 30]. Tissues then were stimulated with cumulative additions of phenylephrine in approximate one-half log increments to generate a concentration-response curve, and contractile tensions were recorded with an online computer. After washing away phenylephrine, tissues were relaxed to the baseline and were recovered at the resting tension for 30 min. The second concentration-response curves of phenylephrine-induced contractions then were repeated in the same tissue in the absence or presence of PDBu (0.03 and 0.1 µM for nonpregnant uterine arteries; 0.3 and 1 µM for pregnant uterine arteries; 10 min) alone and/or in combination with GF109203X (0.1, 0.3, and 1 µM for 20 min), PRKC isozyme-selective inhibitory peptides for conventional PRKC, PRKCB1, PRKCB2, or PRKCE (3 µM for 20 min). The effects of PDBu and PRKC inhibitors on phenylephrine-induced contractions were determined by comparing the two phenylephrine-induced concentration-response curves in the same tissues before and after the treatment with PDBu and the inhibitors. Time control studies showed no significant time-related shift of phenylephrine-response curves. Contractions were expressed as percentage of the KCl response.

Measurement of PRKC Isozyme Translocation

PDBu-stimulated PRKC isozyme translocation and contractions were measured simultaneously in the same uterine arteries. Pregnant and nonpregnant uterine artery rings were equilibrated in the tissue bath, and the optimal tensions were obtained. Tissues then were subjected to stimulation with PDBu (0.2 µM for nonpregnant; 1 µM for pregnant) for 10 min. At the end of treatment, the tissues were quickly frozen in liquid N2, and cytosolic and particulate fractions were prepared as previously described [13]. Briefly, the tissues were homogenized in ice-cold homogenization buffer A containing Tris-HCl 20 mM, sucrose 250 mM, EDTA 5 mM, EGTA 5 mM, β-mercaptoethanol 10 mM, benzamidine 1 mM, phenylmethylsulfonyl fluoride 1 mM, leupetin 50 µM, dithiothreitol 1 mM, and aprotinin 2 µg/ml, pH 7.5. The homogenates were centrifuged at 100 000 x g for 20 min at 4°C, and the supernatants were collected and used as the cytosolic fraction. The pellets were resuspended in homogenization buffer A containing 1% Triton X-100 by stirring overnight at 4°C, diluted with the buffer A to a final concentration of 0.2% Triton X-100, and then centrifuged at 100 000 x g for 20 min at 4°C. The supernatants were collected and referred to as the particulate fraction. Protein concentrations were determined with a protein assay kit (Bio-Rad). Protein samples (5 µg) of particulate fractions were subjected to electrophoresis on 7.5% sodium dodecylsulfate-polyacrylamide gel, and then transferred electrophoretically to nitrocellulose membranes. The membranes were incubated at room temperature for 1 h in Tris-buffered saline solution containing 5% dried milk and 0.5% Tween 20, followed by incubation with primary anti-PRKC isozyme antibodies overnight at 4°C and secondary antibody for 1 h at room temperature. Polyclonal antibodies to PRKCA, PRKCB1, PRKCB2, and PRKCE were used. Bands were detected with enhanced chemiluminsecence (ECL), visualized on Hyperfilm (Amersham, Corp., Arlington Heights, IL), and analyzed with the Kodak 1D image analysis software. To normalize the loading variation of each sample, the corresponding actin level presented in each sample was determined using monoclonal antiactin as primary antibody.

Materials

Phenylephrine, PDBu, GF109203X, and antiactin antibody were obtained from Sigma (St. Louis, MO). Anti-PRKC isozyme antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA). The PRKC isozyme-selective inhibitory peptides for conventional PRKC, PRKCB1, PRKCB2, and PRKCE were from KAI Pharmaceuticals (San Francisco, CA). These peptides were modified with conjugation of peptide carriers via Cys-Cys bonds to facilitate their transportation through biologic membranes into cells. Once in the cells, the Cys-Cys bonds were reduced to enable the exit of the carriers while trapping the peptides inside the cells [28]. In both nonpregnant and pregnant uterine arteries, the peptide carrier alone had no significant effects on PDBu-mediated responses on phenylephrine-induced contractions (data not shown). All electrophoretic and immunoblot reagents were from Bio-Rad. General laboratory reagents were of analytical grade or better and were purchased from Sigma and Fisher Scientific. All drugs were prepared freshly each day and kept on ice throughout the experiment.

Data Analysis

Concentration-response curves were analyzed by computer-assisted nonlinear regression to fit the data using GraphPad Prism (GraphPad Software, San Diego, CA) to obtain the values of pD2 (–log EC50) and the maximum response (Emax). Results were expressed as means ± SEM, and the differences were evaluated for statistical significance (P < 0.05) by one-way ANOVA followed by Neuman-Keuls post-hoc tests.

RESULTS

Effect of GF109203X on Phenylephrine-Induced Contractions

Figure 1 shows that phenylephrine produced concentration-dependent contractions of uterine arteries from both nonpregnant and pregnant ewes. In agreement with the previous findings [5], the pD2 values were significantly increased in uterine arteries from pregnant (6.2 ± 0.1) compared with nonpregnant (5.5 ± 0.1) animals. GF109203X (0.1, 0.3, and 1 µM), a selective inhibitor for conventional and/or novel PRKC isozymes, produced a concentration-dependent inhibition of phenylephrine-induced contractions and shifted the concentration-response curves to the right. As shown in Table 1, in both arteries, 0.3 and 1 µM GF109203X significantly decreased the pD2 values, with no significant effects on the maximal responses.


Figure 01
View larger version (28K):
[in this window]
[in a new window]
[Download PPT slide]
  		FIG. 1 Effect of GF109203X (GF) on concentration-response curves of phenylephrine-induced contractions in uterine arteries. Phenylephrine-induced, concentration-dependent contractions were obtained in the absence or presence of GF109203X (100 nM, 300 nM, and 1 µM). Data are expressed as a percentage of 120 mM KCl-induced response (%KCl) and are means ± SEM of tissues from 4 to 10 animals.


View this table:
[in this window]
[in a new window]
[Download PPT slide]
  		TABLE 1 Effect of GF109203X (GF) on concentration-response curves of phenylephrine-induced contractions in uterine arteries.

Effect of GF109203X on PDBu-Affected Phenylephrine-Induced Contractions

Our previous study demonstrated that PDBu suppressed phenylephrine-induced contractions in pregnant uterine arteries but potentiated the contractions in nonpregnant uterine arteries [13]. Consistent with the previous findings, PDBu (0.3 and 1 µM) dose-dependently inhibited phenylephrine-induced contractions in pregnant uterine arteries, with marked decreases in the maximal response (Fig. 2). GF109203X blocked PDBu-mediated responses and reversed its effect on phenylephrine-induced maximal responses in the pregnant uterine arteries (Table 2). In the presence of 1 µM GF109203X and 0.3 µM or 1 µM PDBu, respectively, the pD2 values of phenylephrine-induced contractions were not significantly different from each other (5.1 ± 0.3 vs. 5.0 ± 0.3; P > 0.05; Table 2), and they were not significantly different from the pD2 value of phenylephrine-induced contractions in the presence of 1 µM GF109203X alone (5.4 ± 0.0; P > 0.05), as shown in Table 1. In nonpregnant uterine arteries, also consistent with the previous findings [13], PDBu (0.03 and 0.1 µM) produced a concentration-dependent potentiation of phenylephrine-induced contractions, with significant increases in the pD2 values but not the maximal responses. GF109203X blocked PDBu-mediated responses (Fig. 3 and Table 3). In the presence of 1 µM GF109203X and 0.03 µM or 0.1 µM PDBu, respectively, the pD2 values of phenylephrine-induced contractions were not significantly different from each other (4.8 ± 0.2 vs. 5.0 ± 0.2; P > 0.05; Table 3), and they were not significantly different from the pD2 value of phenylephrine-induced contractions in the presence of 1 µM GF109203X alone (4.8 ± 0.1; P > 0.05), as shown in Table 1.


Figure 02
View larger version (14K):
[in this window]
[in a new window]
[Download PPT slide]
  		FIG. 2 Effect of GF109203X (GF) on PDBu-inhibted, phenylephrine-induced contractions in pregnant uterine arteries. Phenylephrine-induced, concentration-dependent contractions were obtained in the absence or presence of PDBu (0.3 µM, upper panel; 1 µM, lower panel) and 1 µM GF109203X. Data are expressed as a percentage of 120 mM KCl-induced response (%KCl), and are means ± SEM of tissues from four animals.


View this table:
[in this window]
[in a new window]
[Download PPT slide]
  		TABLE 2 Effect of GF109203X (GF) on PDBu-inhibited phenylephrine-induced contractions in pregnant uterine arteries.


Figure 03
View larger version (16K):
[in this window]
[in a new window]
[Download PPT slide]
  		FIG. 3 Effect of GF109203X (GF) on PDBu-potentiated, phenylephrine-induced contractions in nonpregnant uterine arteries. Phenylephrine-induced, concentration-dependent contractions were obtained in the absence or presence of PDBu (0.03 µM, upper panel; 0.1 µM, lower panel) and 1 µM GF109203X. Data are expressed as a percentage of 120 mM KCl-induced response (%KCl) and are means ± SEM of tissues from four animals.


View this table:
[in this window]
[in a new window]
[Download PPT slide]
  		TABLE 3 Effect of GF109203X (GF) on PDBu-potentiated phenylephrine-induced contractions in nonpregnant uterine arteries.

Effect of PRKC Isozyme-Selective Inhibitory Peptides on PDBu-Affected Phenylephrine-Induced Contractions

To determine the cause and effect relations between individual PRKC isozymes and PDBu-mediated responses, we determined the effects of PRKC isozyme-selective inhibitory peptides for conventional PRKC, PRKCB1, PRKCB2, and PRKCE on PDBu-mediated effects on phenylephrine-induced contractions in pregnant and nonpregnant uterine arteries. In pregnant uterine arteries, there were no significant differences in the pD2 values of phenylephrine-induced contractions among the treatment groups (Table 4). PDBu-mediated inhibition of the maximal response of phenylephrine-induced contractions was partially blocked by specific conventional PRKC, PRKCB1, PRKCB2, and PRKCE inhibitory peptides (Fig. 4 and Table 4). In nonpregnant uterine arteries, PDBu-mediated increases in the pD2 of phenylephrine-induced contractions were inhibited with PRKC isozyme-selective inhibitory peptides for conventional PRKC, PRKCB1, PRKCB2, and PRKCE (Fig. 5 and Table 4). The maximal responses were not significantly different among the treatment groups in nonpregnant uterine arteries (Table 4).


View this table:
[in this window]
[in a new window]
[Download PPT slide]
  		TABLE 4 Effect of PRKC isozyme-selective translocation inhibitory peptides (TIP) on PDBu-affected phenylephrine-induced contractions in uterine arteries.


Figure 04
View larger version (18K):
[in this window]
[in a new window]
[Download PPT slide]
  		FIG. 4 Effect of PRKC isozyme-selective translocation inhibitory peptides (TIP) on PDBu-inhibited, phenylephrine-induced contractions in pregnant uterine arteries. Phenylephrine-induced, concentration-dependent contractions were obtained in the absence or presence of PDBu (1 µM) and conventional PRKC (cPRKC) TIP (3 µM), PRKCB1 TIP (3 µM), PRKCB2 TIP (3 µM), and PRKCE TIP (3 µM), respectively. Data are expressed as a percentage of 120 mM KCl-induced response (%KCl), and are means ± SEM of tissues from six animals.


Figure 05
View larger version (21K):
[in this window]
[in a new window]
[Download PPT slide]
  		FIG. 5 Effect of PRKC isozyme-selective translocation inhibitory peptides (TIP) on PDBu-potentiated, phenylephrine-induced contractions in nonpregnant uterine arteries. Phenylephrine-induced, concentration-dependent contractions were obtained in the absence or presence of PDBu (0.1 µM) and conventional PRKC (cPRKC) TIP (3 µM), PRKCB1 TIP (3 µM), PRKCB2 TIP (3 µM), and PRKCE TIP (3 µM), respectively. Data are expressed as a percentage of 120 mM KCl-induced response (%KCl), and are means ± SEM of tissues from four animals.

PDBu-Induced Translocation of PRKC Isozymes in Uterine Arteries

In pregnant uterine arteries, PDBu significantly increased the levels of PRKCA (137%), PRKCB1 (229%), PRKCB2 (22%), and PRKCE (566%) in membrane particulate fractions, suggesting that PDBu induced translocation and activation of all four PRKC isozymes in pregnant vessels (Fig. 6). In nonpregnant uterine arteries, PDBu significantly increased the levels of PRKCB1 (74%), PRKCB2 (258%), and PRKCE (153%) in membrane particulate fractions without affecting PRKCA levels, suggesting that PDBu induced translocation and activation of PRKCB1, PRKCB2, and PRKCE, but not PRKCA, in nonpregnant vessels (Fig. 6).


Figure 06
View larger version (43K):
[in this window]
[in a new window]
[Download PPT slide]
  		FIG. 6 PDBu-induced membrane translocation of PRKC isozymes in uterine arteries. Membrane translocation of PRKC isozymes was determined with Western blotting, as described in Materials and Methods. The results are expressed as a percentage of control of each isozyme blotted in the same membrane. Data are means ± SEM of tissues from four animals. *P < 0.05 versus control.

DISCUSSION

The present study has demonstrated that PRKC activation is involved in {alpha}1-adrenergic receptor-mediated contractions in ovine uterine arteries and is responsible for the effects of PDBu on {alpha}1-adrenergic receptor-mediated contractions of nonpregnant and pregnant uterine arteries. More importantly, individual isozymes of conventional PRKC, PRKCB, and PRKCE were identified to be involved in the PDBu-mediated responses.

It has been suggested that PRKC plays a key role in {alpha}1-adrenergic receptor-mediated smooth muscle contractions [21, 31–35]. In agreement with the previous findings, the present study showed that GF109203X, an inhibitor for conventional and novel PRKC isozymes, concentration-dependently inhibited phenylephrine-induced contractions in both nonpregnant and pregnant uterine arteries. The relative inhibition produced by GF109203X was similar in uterine arteries from nonpregnant and pregnant animals. This suggests a role of conventional and novel PRKC isozymes in {alpha}1-adrenergic receptor-mediated contractions in the uterine artery. The concentrations of GF109203X used in the present study were within the range shown to inhibit PRKC in previous studies [20, 22, 26].

Our previous study demonstrated that PDBu inhibited {alpha}1-adrenergic receptor-mediated contractions in pregnant uterine arteries [13]. In the present study, we found that PDBu-mediated responses were blocked by GF109203X, suggesting a cause-effect relation between PRKC activation and PDBu-mediated inhibitory effects in pregnant uterine arteries. The finding that GF109203X has a dual effect on {alpha}1-adrenergic receptor-mediated contractions (i.e., inhibition of {alpha}1-adrenergic receptor-mediated contractions and blockade of PDBu-mediated inhibitory effects on {alpha}1-adrenergic receptor-mediated contractions) is intriguing and suggests a two-compartment model of PRKC in the regulation of {alpha}1-adrenergic receptor-mediated contractions in pregnant uterine arteries. One compartment of PRKC may be tightly associated with {alpha}1-adrenergic receptors and forms a "signalsome," which is activated by phenylephrine and participates in {alpha}1-drenergic receptor-mediated contractions. The other, more diffusely distributed compartment of PRKC locates distal to {alpha}1-adrenergic receptors, which is activated nonselectively by phorbol esters and mediates an inhibitory effect on {alpha}1-adrenergic receptor-mediated contractions. It has been well demonstrated that the function of each PRKC isozyme depends on the subcellular location and the availability of protein substrates that can be phosphorylated by the isozyme at the site of anchoring [28]. Whereas PDBu was used as an experimental tool in the present study, physiologic activation of the diffuse and non-receptor-coupled PRKC compartment has been well demonstrated in response to pressure and stretch of vascular smooth muscle, which plays an important role in the regulation of myogenic tone [36].

The other possibility is that different PRKC isozymes may be involved in the regulation of {alpha}1-adrenergic receptor-mediated responses. GF109203X is a nonselective PRKC inhibitor that blocks both conventional and novel PRKC isozymes. We have demonstrated the presence of PRKCA, PRKCB1, PRKCB2, and PRKCE, but not PRKCC, isozymes in uterine arteries [13]. In the present study, we have used the selective inhibitory peptides for PRKCA, PRKCB1, PRKCB2, and PRKCE isozymes to determine the role of PRKC isozymes in PDBu-mediated responses. The inhibitory activities of these peptides are obtained at an intracellular concentration of 5–50 nM [28]. In pregnant uterine arteries, we found that the inhibitory effect of PDBu on {alpha}1-adrenergic receptor-induced contractions was partially, but significantly, reversed by inhibition of conventional PRKC, PRKCB1, PRKCB2, and PRKCE, respectively, suggesting an involvement of these isozymes in the PDBu-mediated inhibitory effect. Previous studies have shown that overexpression of PRKCB inhibits agonist-induced Ca2+ mobilization, and inhibition of PRKCB results in a dramatic increase in agonist-mediated Ca2+ release [37–39]. In addition, it has been demonstrated that PRKCE inhibits L-type Ca2+ current, and PRKCE inhibition increases phenylephrine-induced maximal contractions [40, 41]. Given our previous finding that PDBu significantly inhibited {alpha}1-adrenergic receptor-mediated increases in intracellular Ca2+ concentrations in pregnant uterine arteries [13], the present results suggest that the inhibitory effect of PDBu on {alpha}1-adrenergic receptor-mediated contractions in pregnant uterine arteries is caused by activation of PRKCB and PRKCE isozymes, resulting in a decrease in {alpha}1-adrenergic receptor-mediated Ca2+ mobilization. This is supported with the finding that PDBu induced a membrane translocation of PRKCB and PRKCE in pregnant uterine arteries. It should be noted that none of these PRKC-isozyme selective peptide inhibitors fully reversed the PDBu-mediated inhibition of phenylephrine-induced contractions in pregnant uterine arteries. This is possibly due to either insufficient inhibitor concentrations or the presence of an additive/synergistic effect of PRKC isozymes in PDBu-mediated responses.

In nonpregnant uterine arteries, it appears that PRKC activation has a consistent and positive regulatory role in {alpha}1-adrenergic receptor-mediated contractions. GF109203X inhibited phenylephrine-stimulated contractions and blocked PDBu-mediated potentiation of phenylephrine-induced contractions. This suggests a single functional compartment of PRKC isozyme(s) in the regulation of {alpha}1-adrenergic receptor-mediated contractions in nonpregnant uterine arteries. Unlike pregnant uterine arteries, PRKCB and PRKCE inhibitor peptides produced a complete inhibition of PDBu-mediated potentiation of {alpha}1-adrenergic receptor-induced contractions in nonpregnant uterine arteries, suggesting that activation of PRKCB and PRKCE isozymes contributes in parallel to the PDBu-mediated effect. Consistent with this finding, PDBu increased the membrane translocation of PRKCB and PRKCE in nonpregnant uterine arteries. The role of PRKCA is not clear at the present, given that PDBu did not increase its membrane translocation. We have recently demonstrated that PDBu potentiates {alpha}1-adrenergic receptor-induced contractions in nonpregnant uterine arteries by increasing the Ca2+ sensitivity [13]. Given the previous findings that PRKCB and PRKCE isozymes regulated vascular smooth muscle contractions by increasing the Ca2+ sensitivity [42–47], the present study suggests that PDBu activates PRKCB and PRKCE and increases the Ca2+ sensitivity, resulting in the potentiation of {alpha}1-adrenergic receptor-induced contractions in nonpregnant uterine arteries.

The finding that activation of PRKCB and PRKCE participates in apparent opposite effects of PDBu on {alpha}1-adrenergic receptor-induced contractions in nonpregnant and pregnant uterine arteries is intriguing and suggests that the dichotomy of PRKC mechanisms in the regulation of {alpha}1-adrenergic receptor-induced contractions in nonpregnant and pregnant uterine arteries is not caused by the activation of different PRKC isozymes. Although previous studies have shown that different PRKC isozymes have unique enzymatic properties, substrates, functions in different blood vessels, and species [11, 15–19], the present study is the first one to show that activation of the same PRKC isozymes (i.e., PRKCB and PRKCE) exhibits opposite effects in the same vessel in different physiologic states (i.e., pregnancy and nonpregnancy). This finding suggests that the downstream mechanisms of PRKC isozymes are involved.

Because the function of each PRKC isozyme requires localization to the specific subcellular sites such as plasma membrane, cytoskeletal filaments, or myofilaments, and ability of the isozyme to phosphorylate substrates co-localized to the sites, the distinct functional effects of the same PRKC isozymes with essentially identical catalytic activities can be achieved by their binding and proximity to a particular set of substrates [28]. It is possible that pregnancy alters the subcellular distribution of PRKC isozymes, resulting in regulation of different sets of substrates in the uterine arteries. We have demonstrated previously that activation of PRKC enhances the contractions in nonpregnant uterine arteries through its effects on thin filament regulatory pathway and activation of extracellular signal-regulated kinase/caldesmon and actin polymerization, but inhibits {alpha}1-adrenergic receptor-mediated contractions in pregnant uterine arteries through downregulation of Ca2+-depedent thick filament pathway and decreased myosin light chain phosphorylation [14].

Taken together, our results suggest a transition of subcellular localization of PRKCB and PRKCE from thin filaments to thick filaments in uterine arteries during pregnancy, resulting in an upregulation in coupling of the PRKC isozymes that inhibit {alpha}1-adrenergic receptor-mediated contractions and a downregulation in coupling of the PRKC isozymes that increase {alpha}1-adrenergic receptor-induced contractions. The uterine circulation during pregnancy functions as a low-resistance shunt to accommodate the large increase of uteroplacental blood flow required for normal fetal development. In addition to growth and remodeling of vessels, the decreased uterine vascular resistance is accomplished by increased endothelial nitric oxide release, decreased myogenic response, and a reversible sympathetic denervation of the uterine artery. Although the decreased sympathetic innervation may sensitize postsynaptic {alpha}1-adrenergic receptor signal pathways, as demonstrated in the present study as well as previous studies [5, 48, 49], the present finding of the increased inhibitory effect of PRKC on {alpha}1-adrenergic receptor-mediated contractions in the pregnant uterine artery reveals another important mechanism in maintaining the low uterine vascular tone in pregnancy. Given the finding that steroid hormones induce modulation of cytosolic and membrane-bound regulatory proteins, including PRKC, and regulate their functions [50–54], future studies are needed to investigate the mechanisms of steroid hormones in pregnancy adaptation of PRKC isozyme subcellular distribution and its role in the regulation of {alpha}1-adrenergic receptor signaling pathways in the uterine arteries

FOOTNOTES

1Supported in part by National Institutes of Health grants HL57787 and HD31226 and by the Loma Linda University School of Medicine. Back

Correspondence: 2Lubo Zhang, Center for Perinatal Biology, Department of Physiology & Pharmacology, Loma Linda University School of Medicine, Loma Linda, CA 92350. FAX: 909 558 4029; e-mail: lzhang{at}llu.edu

Received: 18 June 2007.

First decision: 16 July 2007.

Accepted: 17 September 2007.

REFERENCES

  1. Ford SP. Control of blood flow to the gravid uterus of domestic livestock species J Anim Sci 1995 731852–1860[Abstract]
  2. Rosenfeld CR. Mechanisms regulating angiotensin II responsiveness by the uteroplacental circulation Am J Physiol Regul Integr Comp Physiol 2001 281R1025–R1040[Abstract/Free Full Text]
  3. Xiao D and Zhang L. ERK MAP kinases regulate smooth muscle contraction in ovine uterine artery: effect of pregnancy Am J Physiol Heart Circ Physiol 2002 282H292–H300[Abstract/Free Full Text]
  4. Bird IM, Zhang L, Magness RR. Possible mechanisms underlying pregnancy-induced changes in uterine artery endothelial function Am J Physiol Regul Integr Comp Physiol 2003 284R245–R258[Abstract/Free Full Text]
  5. Xiao D and Zhang L. Adaptation of uterine artery thick- and thin- filament regulatory pathway to pregnancy Am J Physiol Heart Circ Physiol 2005 288H142–H148[Abstract/Free Full Text]
  6. Magness RR and Rosenfeld CR. Systemic and uterine responses to alpha-adrenergic stimulation in pregnant and nonpregnant ewes Am J Obstet Gynecol 1986 155897–904[Medline]
  7. Stjernquist M and Owman CH. Adrenoceptors mediating contraction in the human uterine artery Human Reprod 1990 519–24[Abstract/Free Full Text]
  8. Zhang L, Pearce WJ, Longo LD. Noradrenaline-mediated contractions of ovine uterine artery: role of inositol 1, 4, 5-trisphosphate Eur J Pharmacol 1995 287375–382
  9. Cox BE, Roy TA, Rosenfeld CR. Angiotensin II mediates uterine vasoconstriction through alpha-stimulation Am J Physiol Heart Circ Physiol 2004 287H126–H134[Abstract/Free Full Text]
  10. Minneman KP. Alpha 1-adrenergic receptor subtypes, inositol phosphates, and sources of cell Ca2+ Pharmacol Rev 1988 4087–119[Medline]
  11. Nishizuka Y. Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C Science 1992 258607–614[Abstract/Free Full Text]
  12. Xiao D, Buchholz JN, Zhang L. Pregnancy attenuates uterine artery pressure-dependent vascular tone: role of PKC/ERK pathway Am J Physiol Heart Circ Physiol 2006 290H2337–H2343[Abstract/Free Full Text]
  13. Zhang H, Xiao D, Longo LD, Zhang L. Regulation of alpha1-adrenoceptor- mediated contractions of uterine arteries by PKC: effect of pregnancy Am J Physiol Heart Circ Physiol 2006 291H2282–H2289[Abstract/Free Full Text]
  14. Zhang H and Zhang L. Regulation of alpha1-adrenoceptor-mediated contractions of the uterine artery by PKC: role of the thick and thin filament regulatory pathways J Pharmacol Exp Ther 2007 3221253–1260[Abstract/Free Full Text]
  15. Khalil RA, Lajoie C, Resnick MS, Morgan KG. Ca2+-independent isoforms of protein kinase C differentially translocate in smooth muscle Am J Physiol Cell Physiol 1992 263C714–C719[Abstract/Free Full Text]
  16. Liou YM and Morgan KG. Redistribution of protein kinase C isoforms in association with vascular hypertrophy of rat aorta Am J Physiol Cell Physiol 1994 267C980–C989[Abstract/Free Full Text]
  17. Horowitz A, Menice CB, Laporte R, Morgan KG. Mechanisms of smooth muscle contraction Physiol Rev 1996 76967–1003[Abstract/Free Full Text]
  18. Kanashiro CA and Khalil RA. Signal transduction by protein kinase C in mammalian cells Clin Exp Pharmacol Physiol 1998 25974–985[Medline]
  19. Kanashiro CA and Khalil RA. Gender-related distinctions in protein kinase C activity in rat vascular smooth muscle Am J Physiol Cell Physiol 2001 280C34–C45[Abstract/Free Full Text]
  20. Toullec D, Pianetti P, Coste H, Bellevergue P, Grand-Perret T, Ajakane M, Baudet V, Boissin P, Boursier E, Loriolle F, Duhamel L, Charon D, et al. The bisindolylmaleimide GF 109203X is a potent and selective inhibitor of protein kinase C J Biol Chem 1991 26615771–15781[Abstract/Free Full Text]
  21. Gailly P, Gong MC, Somlyo AV, Somlyo AP. Possible role of atypical protein kinase C activated by arachidonic acid in Ca2+ sensitization of rabbit smooth muscle J Physiol 1997 50095–109[CrossRef][Medline]
  22. Damron DS, Kanaya N, Homma Y, Kim SO, Murray PA. Role of PKC, tyrosine kinases, and Rho kinase in alpha-adrenoreceptor-mediated PASM contraction Am J Physiol Lung Cell Mol Physiol 2002 283L1051–L1064[Abstract/Free Full Text]
  23. Nakano Y, Kusama N, Kajikuri J, Suzuki Y, Kanmura Y, Itoh T. Role of PKC in the attenuation of the cGMP-mediated relaxation of skinned resistance artery smooth muscle seen in glyceryl-trinitrate-tolerant rabbit Br J Pharmacol 2004 141391–398[CrossRef][Medline]
  24. Giardina JB, Tanner DJ, Khalil RA. Oxidized-LDL enhances coronary vasoconstriction by increasing the activity of protein kinase C isoforms {alpha} and {varepsilon} Hypertension 2001 37561–568[Abstract/Free Full Text]
  25. Sirous ZN, Fleming JB, Khalil RA. Endothelin-1 enhances eicosanoids- induced coronary smooth muscle contraction by activating specific protein kinase C isoforms Hypertension 2001 37497–504[Abstract/Free Full Text]
  26. Chu L, Takahashi R, Norota I, Miyamoto T, Takeishi Y, Ishii K, Kubota I, Endoh M. Signal transduction and Ca2+ signaling in contractile regulation induced by crosstalk between endothelin-1 and norepinephrine in dog ventricular myocardium Circ Res 2003 921024–1032[Abstract/Free Full Text]
  27. Csukai M and Mochly-Rosen D. Pharmacologic modulation of protein kinase C isozymes: the role of RACKs and subcellular localization Pharmacol Res 1999 39253–259[CrossRef][Medline]
  28. Dorn GW and Mochly-Rosen D. Intracellular transport mechanisms of signal transducers Annu Rev Physiol 2002 64407–429[CrossRef][Medline]
  29. Bright R and Mochly-Rosen D. The role of protein kinase C in cerebral ischemic and reperfusion injury Stroke 2005 362781–2790[Abstract/Free Full Text]
  30. Xiao D and Zhang L. Calcium homeostasis and contractions of the uterine artery: Effect of pregnancy and chronic hypoxia Biol Reprod 2004 701171–1177[Abstract/Free Full Text]
  31. Nishimura J, Khalil RA, Drenth JP, van Breemen C. Evidence for increased myofilament Ca2+ sensitivity in norepinephrine-activated vascular smooth muscle Am J Physiol Heart Circ Physiol 1990 259H2–H8[Abstract/Free Full Text]
  32. Buus CL, Aalkjaer C, Nilsson H, Juul B, Moller JV, Mulvany MJ. Mechanisms of Ca2+ sensitization of force production by noradrenaline in rat mesenteric small arteries J Physiol 1998 510577–590[Abstract/Free Full Text]
  33. Kitazawa T, Eto M, Woodsome TP, Brautigan DL. Agonists trigger G protein-mediated activation of the CPI-17 inhibitor phosphoproteine of myosin light chain phosphatase to enhance vascular smooth muscle contractility J Biol Chem 2000 2759897–9900[Abstract/Free Full Text]
  34. Martinez MC, Randriamboavonjy V, Ohlmann P, Komas N, Duarte J, Schneider F, Stoclet JC, Andriantsitohaina R. Involvement of protein kinase C, tyrosine kinases, and Rho kinase in Ca2+ handling of human small arteries Am J Physiol Heart Circ Physiol 2000 279H1228–H1238[Abstract/Free Full Text]
  35. Sato K, Dohi Y, Suzuki S, Miyagawa K, Takase H, Kojima M, van Breemen C. Role of Ca2+-sensitive protein kinase C in phenylephrine enhancement of Ca2+ sensitivity in rat tail artery J Cardiovasc Pharmacol 2001 38347–355[CrossRef][Medline]
  36. Davis MJ and Hill MA. Signaling mechanisms underlying the vascular myogenic response Physiol Rev 1999 79387–423[Abstract/Free Full Text]
  37. Hua H, Munk S, Goldberg H, Fantus IG, Whiteside CI. High glucose- suppressed endothelin-1 Ca2+ signaling via NADPH oxidase and diacylglycerol-sensitive protein kinase C isozymes in mesangial cells J Biol Chem 1993 27833951–33962[CrossRef]
  38. Kang SW, Wahl MI, Chu J, Kitaura J, Kawakami Y, Kato RM, Tabuchi R, Tarakhovsky A, Kawakami T, Turck CW, Witte ON, Rawlings DJ. PKCbeta modulates antigen receptor signaling via regulation of Btk membrane localization EMBO J 2001 205692–5702[CrossRef][Medline]
  39. Vuong PT, Malik AB, Nagpala PG, Lum H. Protein kinase C beta modulates thrombin-induced Ca2+ signaling and endothelial permeability increase J Cell Physiol 1998 175379–387[CrossRef][Medline]
  40. Grimm M, Mahnecke N, Soja F, El-Armouche A, Haas P, Treede H, Reichenspurner H, Eschenhagen T. The MLCK-mediated {alpha}1-adrenergic inotropic effect in atrial myocardium is negatively modulated by PKC{varepsilon} signaling Br J Pharmacol 2006 148991–1000[CrossRef][Medline]
  41. Hu K, Mochly-Rosen D, Boutjdir M. Evidence for functional role of {varepsilon}PKC isozyme in the regulation of cardiac Ca2+ channels Am J Physiol Heart Circ Physiol 2000 279H2658–H2664[Abstract/Free Full Text]
  42. Singer HA, Schworer CM, Sweeley C, Benscoter H. Activation of protein kinase C isozymes by contractile stimuli in arterial smooth muscle Arch Biochem Biophys 1992 299320–329[CrossRef][Medline]
  43. Walsh MP, Andrea JE, Allen BG, Clement-Chomienne O, Collins EM, Morgan KG. Smooth muscle protein kinase C Can J Physiol Pharmacol 1994 721392–1399[Medline]
  44. Walsh MP, Horowitz A, Clement-Chomienne O, Andrea JE, Allen BG, Morgan KG. Protein kinase C mediation of Ca2+-independent contractions of vascular smooth muscle Biochem Cell Biol 1996 74485–502[Medline]
  45. Bitar KN, Hillemeier C, Biancani P, Balazovich KJ. Regulation of smooth muscle contraction in rabbit internal anal sphincter by protein kinase C and Ins(1,4,5)P3 Am J Physiol 1991 260G537–G542[Medline]
  46. Horowitz A, Clément-Chomienne O, Walsh MP, Morgan KG. Epsilon- isoenzyme of protein kinase C induces a Ca2+-independent contraction in vascular smooth muscle Am J Physiol 1996 271C589–C594[Medline]
  47. Dessy C, Matsuda N, Hulvershorn J, Sougnez CL, Sellke FW, Morgan KG. Evidence for involvement of the PKC-alpha isoform in myogenic contractions of the coronary microcircul ation Am J Physiol Heart Circ Physiol 2000 279H916–H923[Abstract/Free Full Text]
  48. Annibale DJ, Rosenfeld CR, Kamm KE. Alterations in vascular smooth muscle contractility during ovine pregnancy Am J Physiol 1989 256H1282–H1288[Medline]
  49. D'Angelo G and Osol G. Regional variation in resistance artery diameter responses to alpha-adrenergic stimulation during pregnancy Am J Physiol 1993 264H78–H85[Medline]
  50. Kelly MJ and Levin ER. Rapid actions of plasma membrane estrogen receptors Trends Endocrinol Metab 2001 12152–156[CrossRef][Medline]
  51. Orshal JM and Khalil RA. Gender, sex hormones, and vascular tone Am J Physiol Regul Integr Comp Physiol 2004 286R233–R249[Abstract/Free Full Text]
  52. Simoncini T, Hafezi-Moghadam A, Brazil DP, Ley K, Chin WW, Liao JK. Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-OH kinase Nature 2000 407538–541[CrossRef][Medline]
  53. Simoncini T, Fornari L, Mannella P, Varone G, Caruso A, Liao JK, Genazzani AR. Novel non-transcriptional mechanisms for estrogen receptor signaling in the cardiovascular system: Interaction of estrogen receptor {alpha} with phosphatidylinositol 3-OH kinase Steroids 2002 67935–939[CrossRef][Medline]
  54. Tostes RC, Nigro D, Fortes ZB, Carvalho MH. Effects of estrogen on the vascular system Estrogen and the vascular system Braz J Med Biol Res 2003 361143–1158[Medline]




This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
78/1/35    most recent
biolreprod.107.063479v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zhang, H.
Right arrow Articles by Zhang, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zhang, H.
Right arrow Articles by Zhang, L.
Agricola
Right arrow Articles by Zhang, H.
Right arrow Articles by Zhang, L.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS